Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Filing tables
Filing exhibits
- 10-K Annual report
- 4.13 Description of Securities of Inmed Pharmaceuticals Inc
- 10.13 Consulting Agreement Dated As of April 1, 2022, Between Inmed Pharmaceuticals Inc. and Brenda Edwards
- 21.1 Subsidiaries of the Company
- 23.1 Consent of Marcum LLP
- 23.2 Consent of KPMG LLP
- 31.1 Certification
- 31.2 Certification
- 32.1 Certification
- 32.2 Certification
- Download Excel data file
- View Excel data file
INM similar filings
Filing view
External links
Exhibit 32.2
Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Jonathan Tegge, the Chief Financial Officer of InMed Pharmaceuticals Inc. (the “Company”), hereby certify that, to my knowledge:
1. The Annual Report on Form 10-K for the year ended June 30, 2023 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: September 29, 2023
/s/ Jonathan Tegge | ||
Name: | Jonathan Tegge | |
Title: | Interim Chief Financial Officer |